


Selgantolimod

Chemical Properties

CAS No. :	2004677-13-6
Formula:	C ₁₄ H ₂₀ FN ₅ O
Molecular Weight:	293.34
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment of the hepatitis B virus and human immunodeficiency virus infection.
Targets(IC50)	HBV,TLR
In vitro	Selgantolimod induces the cellular immune mediators interleukin (IL)-12 and IL-8, as well as the antiviral cytokines tumor necrosis factor- α and interferon- γ in vitro in human peripheral blood mononuclear cells. These cytokines reduce HBV DNA, RNA, and antigen levels in HBV-infected primary human hepatocytes. Selgantolimod activates natural killer and mucosal-associated invariant T cells, stimulates cluster of differentiation (CD) -8+ T-cell proliferation, and increases IFN γ production while lowering programmed cell death protein 1 expression by HBV-specific CD8+-T cells in vitro in peripheral blood mononuclear cells [1].
In vivo	Selgantolimod (p.o., once-weekly) treatment induces dose-dependent increases in serum IL-12 and IL-1 receptor antagonist (IL-1RA) in cynomolgus monkeys and causes functional cure in the woodchuck model of chronic HBV [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.409 mL	17.0451 mL	34.0901 mL
5 mM	0.6818 mL	3.409 mL	6.818 mL
10 mM	0.3409 mL	1.7045 mL	3.409 mL
50 mM	0.0682 mL	0.3409 mL	0.6818 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12.

Benjamin Ryan. Selgantolimod Shows Promise as Treatment for Hepatitis B. November 18, 2019.

Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment of hiv. US20170071944A1.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481